EP07.04-17 Study on the Regulatory Mechanism of OM-85 BV on the Immune Microenvironment of Clinical Early-stage Lung Adenocarcinoma

Clinically, early-stage lung cancer mostly presents as lung nodules, and the incidence of lung nodules in China is about 10%-20%, of which the chance of malignant lesions is about 5%. OM-85 Broncho-Vaxom (BV) is a bacterial lysis product that has been shown to have immunomodulatory effects. This study investigates the immunomodulatory effects and possible mechanisms of OM-85 BV on early-stage lung adenocarcinoma. In turn, it provides an effective strategy for early treatment.